Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 9/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151038 | 1.00 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL1036062 | 1.00 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL16701320 | 0.90 | CALML3 (0.49) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL16701317 | 0.90 | CALML3 (0.49) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL4574440 | 0.87 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537758 | 0.85 | CALML3 (0.45) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537751 | 0.85 | CALML3 (0.45) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537986 | 0.84 | CALML3 (0.44) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7538108 | 0.83 | MAOA (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL3166083 | 0.83 | GRM2 (0.58) | CALML3MAOAMAOBGRM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442526-B1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3442526-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Melinta Subsidiary Corp. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| WO-2017200979-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-3217974-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | Melinta Therapeutics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| WO-2016077818-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA THERAPEUTICS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | MELINTA SUBSIDIARY CORP. | 2013-03-14 | — | — | US | disclosed |
| US-8324398-B2 | Process for the synthesis of biaryl oxazolidinones | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-7129259-B2 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060148869-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | CHEN SHILI | 2006-07-06 | — | — | US | disclosed |
| EP-1660465-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050153971-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-07-14 | — | — | US | disclosed |
| WO-2005012271-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | RIB-X PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153971-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | PROKR1, PROKR2, PCNA | CALML3 4062/4885CYP3A4 356/4885CYP2D6 139/4885 |
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | PCNA, PGC, SBDS | CALML3 4667/4885CYP3A4 76/4885CYP2D6 94/4885 |
| US-20100234615-A1 | Process for the synthesis of triazoles | PROKR1, SI, IL33 | CALML3 4426/4885CYP3A4 14/4885CYP2D6 160/4885 |
| US-20060148869-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | PCNA, PROKR1, BCOR | CALML3 4101/4885CYP3A4 320/4885CYP2D6 133/4885 |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | CALML3 4706/4885CYP3A4 62/4885CYP2D6 60/4885 |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | CALML3 2223/4885CYP3A4 1383/4885CYP2D6 1764/4885 |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | CUTA, CYP17A1, HSD17B11 | CALML3 4401/4885CYP3A4 957/4885CYP2D6 1856/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | CALML3 4401/4885CYP3A4 957/4885CYP2D6 1856/4885 |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | PROKR1, SI, IL33 | CALML3 4426/4885CYP3A4 14/4885CYP2D6 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.